Solstice Oncology raises $225m Series A for cancer immunotherapy

Testing an immune therapy before surgery

Solstice is developing porustobart, a second-generation, Fc-enhanced CTLA-4 antibody, for use with pembrolizumab before surgery. The company is evaluating the combination in a Phase 2 trial for stage II–III microsatellite-stable colon cancer and a second undisclosed indication.

Solstice focuses on the neoadjuvant setting, where treatment is given before an operation. The company says the Series A will advance porustobart across both indications; the candidate remains in clinical development.

Use of funds

Advance lead candidate porustobart in two clinical indications

Funding history

Sep 9, 2026Series A · This round$225M

Sources

Similar rounds

All Biotech rounds →

Aventix

Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.

€1.2MPre-seed · Sep 30, 2026

AnaCardio

AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.

€62.5MSeries B · Sep 30, 2026

Aptadir Therapeutics

RNA therapeutics designed to restore expression of silenced genes

€40MSeed · Sep 29, 2026

MOYOM Biotech

Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments.

UndisclosedFinancing round · Sep 28, 2026